

O I P E
MAR 25 2002

Form PTO 1449 US Department of Commerce Patent and Trademark Office	ATTY DOCKET NO: P-IX 2965	SERIAL NO. 09/016,061
	APPLICANT: William D. Huse	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: January 30, 1998	GROUP: 1644

COPY OF PAGES
ORIGINALLY FILED

U.S. PATENT DOCUMENTS

EXAM. INITIALS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	US 6,180,370 B1	1/30/01	Queen et al.	435	69.6	6/7/95

RECEIVED
APR 03 2002

FOREIGN PATENT DOCUMENTS

TECH CENTER 1600/2900

EXAM. INITIALS	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION (YES/NO)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

	BIOTECHNOLOGY NEWSWATCH, pp. 11-12, 1/16/95
	BIOTECHNOLOGY NEWSWATCH, pp. 11, 2/6/95
	Studnicka et al., "Human engineered monoclonal antibodies retain full specific binding activity by preserving non-CDR complementarity-modulating residues," <u>Protein Engineering</u> 7:805-814 (1994)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.